Scarica l'app Stockscreener
1.53
2.68%
0.04
Dopo l'orario di chiusura:
1.53
Precedente Chiudi:
$1.49
Aprire:
$1.53
Volume 24 ore:
722.21K
Relative Volume:
3.74
Capitalizzazione di mercato:
$21.95M
Reddito:
-
Utile/perdita netta:
$-8.29M
Rapporto P/E:
-2.5932
EPS:
-0.59
Flusso di cassa netto:
$-6.47M
1 W Prestazione:
+3.38%
1M Prestazione:
+14.18%
6M Prestazione:
-15.93%
1 anno Prestazione:
+41.67%
Intervallo 1D:
$1.50
$1.5509
Intervallo di 1 settimana:
$1.4201
$1.5509
Portata 52W:
$1.0001
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Confronta NNVC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.53 | 21.95M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors USA
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News
NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz
NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA
NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News
NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news
NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA
Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
NNVC - Insider Financial
Chronic Fatigue Syndrome Market Demand and Opportunities - openPR
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick
Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey
7 Best Nanotech Penny Stocks to Buy - Insider Monkey
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit - MSN
Genital Herpes Research and Development Pipeline Market By Application, Size, Share, And Forecast (2024-2034) - Daily News Mirror
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow - Oil City Derrick
Apparent Israeli airstrike on mosque in central Gaza kills at least 18 people - Source ONE News
NanoViricides (NYSE:NNVC) Trading 4.3% Higher – Time to Buy? - Defense World
Marburgvirus Infection Industry value, Share, Technology to (2024-2036) - Daily News Mirror
Marburgvirus Infection Industry Size, Share, Technology to (2024-2034) - La Funcion mx
Oasis adds US, Canada and Mexico stops to 2025 tour - Oil City Derrick
NanoViricides prepares for Phase II trials for antiviral NV-387 - Proactive Investors USA
No arrests in South Africa mass shootings as death toll rises to 18 - Oil City Derrick
Over 90,000 Georgia residents sheltering a day after chemical plant fire sends chlorine into the air - Oil City Derrick
Rwanda reports 8 deaths linked to Ebola-like Marburg virus days after it declared an outbreak - Oil City Derrick
AT&T exits showbiz, sells remaining stake in DirecTV to private equity firm TPG for $7.6 billion - Oil City Derrick
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID - Source ONE News
China factory surveys show economy weakening, as Beijing steps up support - Oil City Derrick
Vance criticized an infrastructure law as a candidate then embraced it as a senator - Oil City Derrick
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM) - Oil City Derrick
Orbán aide faces backlash for saying Hungary wouldn’t have fought a Russian invasion - Oil City Derrick
The number of Americans filing for jobless aid falls to lowest level in four months - Oil City Derrick
NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement - Proactive Investors UK
Brimma Tech Unveils Advanced AUS Sandbox Solution for Enhanced Mortgage Underwriting - Oil City Derrick
Harrods apologizes to women who say they were abused by former owner Mohamed Al Fayed - Oil City Derrick
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):